Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBio-Sustainable Future Enterprises Regulatory News (BSFA)

Share Price Information for Bio-Sustainable Future Enterprises (BSFA)

Share Price is delayed by 15 minutes
Get Live Data
1.125    0.00 (0.00%)
Bid:
1.00
Ask:
1.25
Spread: 0.25 (25.00%)
Market Cap: £2.18m
BSFA Live PriceLast checked at - London Stock Exchange

Intraday Bio-Sustainable Future Enterprises Share Chart

First Tannable A4-Sized Skin Achieved

10 Mar 2026 10:47

RNS Number : 0672W
BSF Enterprise PLC
10 March 2026
 

10 March 2026

BSF Enterprise PLC

First Tannable A4-Sized Skin Achieved

Scalable Process Unlocked for Elemental™; T-Rex Leather™ Showcase Confirmed for 2 April 2026

BSF Enterprise PLC (LSE:BSFA), the tissue-engineering innovator, is pleased to report a significant commercial milestone for its wholly-owned subsidiary Lab-Grown Leather Limited ("LGL"): the successful production of a fully tanned, scaffold-free skin reaching A4 sheet size and approaching 2mm thickness - achieved in a matter of weeks using LGL's proprietary Advanced Tissue Engineering Platform ("ATEP™").

 

Key Milestones Achieved

• A4-size tannable skin produced at industrially relevant thickness (~2mm)

• Scalable process developed over the last six months using ATEP™

• Scaffold-free architecture delivering bio-equivalent durability, breathability and patina

• Zero-waste geometry: skin cultivated to specification, eliminating traditional hide scrap rates

• T-Rex Leather™ website and social channels live; showcase event confirmed for 2 April 2026

 

Elemental™: A New Standard for High-Performance Luxury Materials

The Elemental™ product series represents the commercial embodiment of LGL's ATEP™. Over the past six months, the LGL team has engineered a repeatable, scalable process that takes animal cells and cultivates them into a tannable skin product at dimensions that are meaningful to luxury goods manufacturers. This first full tanning of the material - a critical processing step required before leather can be used in finished goods - confirms that Elemental™ is advancing through the technical readiness pathway towards commercial supply.

 

Unlike many competing bio-based or synthetic alternative materials, LGL's scaffold-free approach means the cells self-organise to produce a material that is bio-equivalent to conventional hide: retaining the structural integrity, tactile properties, and characteristic patina that luxury brands demand. The process can be tuned to produce leathers that are thinner, stronger, or with unique surface characteristics that would be impossible or unethical to source conventionally. Thus LGL is able to uniquely position ElementalTM as a high-end, low-intervention material, setting the standard for a new generation of leather and cultivating a new era for luxury.

 

T-Rex Leather™ - Where Technology Meets Rarity

One of the most distinctive and commercially compelling applications of LGL's platform is its ability to engineer material inspired by the cellular biology of rare and extinct species. T-Rex Leather™ leverages this capability to offer the luxury and fashion industries access to materials that are, by definition, unavailable by any other means - creating a genuine scarcity narrative that is entirely authentic and ethically sound.

 

This positions LGL in a unique category: not simply a "more sustainable" version of existing leather, but a genuinely new class of luxury material with intrinsic rarity, provenance, and a powerful story. The T-Rex Leather™ brand has now launched its website and social media presence, and a showcase event has been confirmed for 2 April 2026, which the Company expects to generate significant press and industry engagement.

See links:

https://www.instagram.com/t_rex_leather/

https://lab-grown-leather.com/t-rex-leather/

 

Elemental™ skin sample - A4 size, approaching 2mm thickness

Commercial Outlook

The achievement of a tannable skin at A4 scale and industrially relevant thickness is a key gate in LGL's commercialisation roadmap. The Company is now in a position to extend its engagement with luxury goods manufacturers, material distributors, and brand partners on the basis of a tangible, scalable and demonstrable product. LGL's IP-protected ATEP™ platform provides a defensible competitive moat across both the conventional luxury leather market and the emerging exotic/extinct species segment.

 

The Company will continue to update shareholders on progress, including the outcome of the 2 April 2026 T-Rex Leather™ showcase event.

 

END

 

Engage with the BSF Enterprise management team directly by asking questions, watching videosummaries and seeing what other shareholders have to say. Navigate to our Interactive Investorwebsite here:

 

https://bsfenterprise.com/link/ya3aRr

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

BSF Enterprise PLC

Geoff Baker - Chairman

Che Connon - CEO & Director

 

We encourage all investors to share questions on this announcement via our investor website.

https://bsfenterprise.com/s/a1f22b

Shard Capital (Broker)

Damon Heath

Isabella Pierre

 

0207 186 9000

0207 186 9927

AlbR Capital Limited (Broker)

Colin Rowbury

Jon Belliss

+44 (0)20 7469 0930

ISIN of the Ordinary Shares

is GB00BHNBDQ51.

SEDOL Code is BHNBDQ5.

 

 

 

Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43

 

About BSF Enterprise PLC

BSF Enterprise PLC (LSE:BSFA) develops and commercialises cutting-edge tissue-engineered solutions, including lab-grown leather (via LGL), cultivated meat, and corneal repair technologies. By leveraging its proprietary scaffold-free ATEP™ platform, BSF delivers sustainable, high-performance alternatives to conventional materials, targeting global markets where provenance, ethics, and performance are increasingly prized by consumers and brands alike.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDBGGDXBSBDGLG
Date   Source Headline
18th Dec 20247:00 amRNS3DBT Ltd Secures Prestigious Northern Accelerator
4th Dec 20247:00 amRNSOversubscribed Fundraising of £500,000
8th Nov 20247:00 amRNSPortfolio Update
26th Sep 20247:00 amRNSPortfolio Update
12th Aug 20247:00 amRNSKerato Ltd Partners with University of Montreal
18th Jun 20247:00 amRNSDirector/PDMR Shareholding
17th Jun 20247:00 amRNSDirector/PDMR Shareholding
14th Jun 202410:47 amRNSDirector/PDMR Shareholding
13th Jun 20247:00 amRNSGrant of Options
11th Jun 20247:00 amRNSInterim Results
11th Apr 20247:00 amRNSSuccessful Cultivated Leather PoC Agreements
20th Mar 202412:56 pmRNSResult of Annual General Meeting
20th Mar 202410:19 amRNSUniversity Collaborations
14th Mar 20247:00 amRNSInvestor Evening
7th Mar 20247:00 amRNSBSF Enterprise and Ivy Farm Enter Partnership
29th Feb 20247:00 amRNSMoU with Sustainable Fashion Company
26th Feb 20247:27 amRNSNotice of AGM
22nd Feb 20247:00 amRNSKerato Limited - Update
15th Feb 20247:00 amRNSStrategic Update
31st Jan 20247:00 amRNSFull Year Results
8th Dec 20237:00 amRNSFOODTECH Joint Venture with CellRev
30th Nov 20233:07 pmRNSStandard form for notification of major holdings
24th Nov 20237:00 amRNS3D Bio-Tissues Product Partnership Progress
26th Oct 20237:00 amRNSNew Cornea Company & Investor Update
9th Oct 20239:34 amRNSParticipation in The ThinkEquity Conference
26th Sep 20232:32 pmRNSResults of General Meeting & Allotment of Shares
18th Sep 20237:00 amRNS3D Bio-Tissues receives EUR612,000 grant
11th Sep 20237:00 amRNSStrategic Update
7th Sep 20239:46 amRNSPublication of Prospectus & Notice of GM
17th Jul 20237:00 amRNSCity-Mix Bio-Pharmaceutical Update
3rd Jul 20239:56 amRNSOpens Office in Hong Kong
29th Jun 20237:00 amRNSInterim Results
23rd Jun 202311:30 amRNSCultivated Meat Approved for Consumption in US
8th Jun 20237:00 amRNSUS Investor Roadshow & Appointment of US IR Agency
1st Jun 20237:00 amRNSPublication of New Research
30th May 20237:00 amRNSSuccessful Cultivated Meat Test
25th May 20237:00 amRNSAdmittance to trading on the OTCQB Venture Market
22nd May 20237:00 amRNSCommercial Progress Update
15th May 20237:00 amRNSLab-Grown Leather Update and Innovation Award Win
21st Apr 20237:00 amRNSShowcase Meat Update
14th Apr 20238:00 amRNSAdmission of Placing Shares & Subscription Shares
12th Apr 20233:35 pmRNSUpdate to Oversubscribed £2.9 million fundraise
29th Mar 20234:35 pmRNSPrice Monitoring Extension
29th Mar 20237:00 amRNSOversubscribed £2.9 million fundraise
15th Mar 202311:59 amRNSResult of Annual General Meeting
15th Mar 20237:00 amRNSAGM Statement
9th Mar 20238:53 amRNSApplication for Trading on US OTCQB Venture Market
6th Mar 20237:00 amRNSCity-Mix Commercial Progress Update
20th Feb 20233:00 pmRNSNotice of AGM
10th Feb 20237:00 amRNSAllotment of shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.